H. Lundbeck A/S has announced an agreement with the Danish Centre for AI Innovation (DCAI) to leverage Gefion, Denmark's flagship AI supercomputer, for accelerating drug discovery and development in neurological and psychiatric disorders. Lundbeck is among the first pharmaceutical companies to utilize Gefion for this purpose, aiming to address the significant unmet needs in brain health, which affects approximately half the world's population.

By leveraging Gefion's AI computational power, Lundbeck seeks to enhance and expedite the discovery of next-generation treatments. The company anticipates that Gefion will provide AI-driven insights into molecule discovery and drug optimization, facilitating the development of therapies for known drug targets and unlocking emerging ones. This will potentially lead to new treatment options for individuals with brain disorders, including rare and specialist-treated neurological conditions.

Tarek Samad, Senior Vice President & Head of Research at Lundbeck, highlighted the importance of AI-driven innovation in Lundbeck's strategy, stating that Gefion's advanced computational capabilities could help push the boundaries of tackling brain diseases and developing treatments at an unprecedented pace. Nadia Carlsten, CEO of DCAI, noted that this collaboration has the potential to accelerate the timeline for bringing impactful neurological therapies to patients.

Claus Thomsen, Senior Vice President of Global IT at Lundbeck, emphasized the role of AI in Lundbeck's IT strategy, indicating that providing researchers with access to Gefion and its software stack will enable them to leverage AI-driven analysis and large-scale simulations. This agreement marks a significant step towards transforming brain disease research through AI.

Other companies are also utilizing Gefion for various projects, including foundational AI research, human-centric healthcare solutions, and pharmaceutical and biotech innovation. Nadia Carlsten highlighted the potential of AI supercomputing in addressing urgent healthcare challenges.

Lundbeck, a biopharmaceutical company focused on brain health, has over 70 years of experience in neuroscience and is dedicated to improving the lives of people with neurological and psychiatric diseases. The company strives to develop transformative medicines for complex neurological challenges and is committed to fighting stigma and improving health equity. Lundbeck has approximately 5,500 employees in more than 50 countries, with products available in over 80 countries. The Danish Centre for AI Innovation (DCAI) owns and operates Gefion, which ranks among the most powerful supercomputers globally, powered by NVIDIA H100 Tensor Core GPUs. DCAI aims to lower the barrier for accessing advanced computing capabilities, fostering innovation and ecosystem growth.